Group 1 - The Hang Seng Tech Index increased by 3% to 5,857.76 points [1] - Zhihu's stock surged over 30% [1] - Alibaba Health's stock rose by more than 10% [1]

Group 1 - The core viewpoint of the article highlights the strong performance of technology stocks in both A-shares and Hong Kong stocks, particularly in sectors like satellite technology and internet services [1] - The ChiNext Index in A-shares has surpassed 1.7%, indicating a significant upward trend in technology stocks [1] - In Hong Kong, the internet sector, including cloud computing, mobile payments, big data, and software services, has also seen notable gains, with the Hong Kong Stock Connect Internet ETF (159792) rising by 5.43% [1] Group 2 - Institutional analysis suggests that the rising enthusiasm for technology stocks in A-shares is positively influencing the Hong Kong technology market, indicating a potential marginal recovery [1] - The anticipated easing by the Federal Reserve and the economic recovery in mainland China are benefiting new consumption sectors and technology stocks with growth potential amid the AI wave [1] - The Hong Kong Stock Connect Internet ETF (159792) closely tracks the Hong Kong Stock Connect Internet Index, with its top ten constituent stocks including major players like Alibaba, Xiaomi, Tencent, and Meituan, which collectively account for nearly 60% of the ETF's weight [1]

Core Insights - The Huabao CSI Hong Kong Stock Connect Medical Theme ETF (159137) closed with a gain of 0.38% on January 12, with a trading volume of 173 million yuan [1] Fund Overview - The fund was established on December 31, 2025, and is officially named Huabao CSI Hong Kong Stock Connect Medical Theme Exchange-Traded Fund [1] - The management fee is set at 0.50% per annum, while the custody fee is 0.10% per annum [1] - The performance benchmark for the fund is the return of the CSI Hong Kong Stock Connect Medical Theme Index, adjusted for the RMB exchange rate [1] Fund Management - The current fund manager is Zhang Fang, who has managed the fund since its inception, achieving a return of 4.33% during the management period [1] Top Holdings - The latest report indicates that the top holdings of the ETF include: - WuXi Biologics: 2.65% holding, valued at approximately 7.49 million yuan [2] - JD Health: 2.02% holding, valued at approximately 5.71 million yuan [2] - WuXi AppTec: 1.44% holding, valued at approximately 4.07 million yuan [2] - Crystal Digital Holdings: 0.98% holding, valued at approximately 2.76 million yuan [2] - Alibaba Health: 0.93% holding, valued at approximately 2.63 million yuan [2] - WuXi AppTec Holdings: 0.86% holding, valued at approximately 2.43 million yuan [2] - Sinopharm: 0.72% holding, valued at approximately 2.04 million yuan [2] - Genscript Biotech: 0.55% holding, valued at approximately 1.55 million yuan [2] - Ping An Good Doctor: 0.46% holding, valued at approximately 1.31 million yuan [2] - CSPC Pharmaceutical Group: 0.41% holding, valued at approximately 1.17 million yuan [2]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The pharmaceutical sector experienced a weekly return of 7.81%, outperforming the CSI 300 index by 5.03%, ranking 6th among 31 primary sub-industry indices. The medical services sub-sector had the highest weekly increase of 12.34% [3][15] - The report highlights the impact of recent events such as Elon Musk's announcement regarding Neuralink's product mass production in 2026, Arrowhead Pharmaceuticals' promising clinical data for its siRNA therapy ARO-INHBE, and OpenAI's launch of "ChatGPT health," which have driven the sector's performance. The report suggests that while the brain-computer interface theme may be at a short-term emotional peak, AI medical applications still have room for growth [3][14] - Continuous investment in innovative drugs and related assets in the CXO and upstream life sciences sectors is recommended [3][14] Summary by Sections 1. Market Performance - The pharmaceutical sector's monthly return was 4.87%, outperforming the CSI 300 index by 1.37%, ranking 18th among 31 primary sub-industry indices. The medical services sub-sector had the highest monthly increase of 12.19% [15][20] 2. AI Medical Applications - AI applications in healthcare include AI+medical testing, AI+medical large models, AI+imaging, AI+e-commerce/precision marketing, and AI+gene sequencing, with notable companies such as KingMed Diagnostics, Dian Diagnostics, and BGI Genomics leading in these areas [4][16] 3. CXO and Upstream Life Sciences - Key global CXO leaders to watch include WuXi AppTec, WuXi Biologics, and Kelun Pharmaceutical. Domestic clinical CRO leaders include Tigermed and PPD. The report also highlights resource-based CXOs and upstream life sciences companies [5][16] 4. High-end Medical Devices - The report suggests focusing on companies involved in robotic applications, pharmaceutical equipment, and consumer medical devices, as demand is gradually recovering [5][16] 5. Innovative Drugs - Investment opportunities are identified in small nucleic acids, ADCs, and IO dual/multi-antibodies, with specific companies recommended for each category [6][16]

1月12日，港股科技板块走强，AI应用概念股集体爆发截至14:15，香港交易所科技100指数 该指数反映100家在香港交易所上市的市值最大的科技公司的整体表现，涵盖人工智能、生物科技及制 药、电动汽车及智能驾驶、资讯科技、互联网、机器人六大创新主题，突显了香港市场在推动新兴产业 发展方面的关键角色，同时指数成份股均符合南向交易资格，为投资者提供了有效且全面的投资工具， 助力其便捷把握港股科技板块投资机遇。 （文章来源：每日经济新闻） （HKEXT100）上涨2.4%，成分股中，迈富时涨超24%，第四范式涨近19%，金山云涨超14%，趣致集 团、美图公司涨约13%，阿里健康涨超10%。 此前，香港交易所正式推出香港交易所科技100指数，并宣布已与易方达基金签订授权协议。 ...

1月12日，阿里健康午后继续走高，涨超9%，报6.33港元/股。消息面上，据阿里健康官微消息，1月8 日，阿里健康与北京梅尔森医药技术开发有限公司达成战略合作，共同宣布将在儿童专科创新药领域展 开深度合作。 来源：视频滚动新闻 ...

Group 1 - The Hong Kong stock market saw a strong performance on January 12, with significant gains in tech, media, and aerospace sectors, particularly AI concept stocks [1] - Notable performers included Zhihui, which surged nearly 38%, and MINIMAX, which rose over 25% [1] - Other companies that experienced substantial gains include Lion Group (up over 28%), Kingsoft Cloud (up 13%), Meitu (up 11%), and several others in the tech sector [1][2] Group 2 - Bloomberg industry research indicates that the earnings growth of Chinese tech giants is expected to surpass that of the "seven giants" in the US stock market for the first time since 2022, with a significant turning point anticipated in 2026 [3] - DeepSeek is set to release its next-generation V4 model in mid-February, which is expected to excel in programming tasks, long code prompt processing, and improved data pattern understanding [3] - The development of large models is accelerating the commercialization of AI applications, particularly in search & marketing, coding, multimodal applications, agents, and AI for science [3] - The evolution of large models is seen as a key tool for companies with deep industry know-how, particularly in AI healthcare, which is transitioning from a single auxiliary tool to comprehensive lifecycle management [3]

据悉，长期以来，国内缺乏专为婴幼儿设计的外用血管瘤治疗药物。贝美净®不仅是全球首个针对该适 应症的外用凝胶剂型，也标志着我国在儿童专用改良型新药研发领域取得了从科研创新到产业转化的重 大突破。贝美净®(马来酸噻吗洛尔凝胶)将于1月13日在阿里健康全网独家首发。 阿里健康(00241)涨近4%，截至发稿，涨3.29%，报5.96港元，成交额5.19亿港元。 消息面上，据阿里健康官微消息，1月8日，阿里健康与北京梅尔森医药技术开发有限公司达成战略合 作，共同宣布将在儿童专科创新药领域展开深度合作。双方将围绕全球首款获批用于治疗增殖期浅表性 婴儿血管瘤的外用创新药——贝美净®(马来酸噻吗洛尔凝胶)，开展从患者教育、公益援助到全渠道首 发的深度协同。 ...

据悉，长期以来，国内缺乏专为婴幼儿设计的外用血管瘤治疗药物。贝美净不仅是全球首个针对该适应 症的外用凝胶剂型，也标志着我国在儿童专用改良型新药研发领域取得了从科研创新到产业转化的重大 突破。贝美净(马来酸噻吗洛尔凝胶)将于1月13日在阿里健康全网独家首发。 消息面上，据阿里健康官微消息，1月8日，阿里健康与北京梅尔森医药技术开发有限公司达成战略合 作，共同宣布将在儿童专科创新药领域展开深度合作。双方将围绕全球首款获批用于治疗增殖期浅表性 婴儿血管瘤的外用创新药——贝美净(马来酸噻吗洛尔凝胶)，开展从患者教育、公益援助到全渠道首发 的深度协同。 阿里健康(00241)涨近4%，截至发稿，涨3.29%，报5.96港元，成交额5.19亿港元。 ...

Core Viewpoint - The Hong Kong stock market's healthcare sector is experiencing significant activity, particularly in brain-computer interfaces and AI healthcare, with notable gains in various stocks and the launch of a new healthcare ETF [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect healthcare sector index has risen for seven consecutive days since the beginning of 2026, with a peak increase of over 1% on January 12 [1]. - Notable stock performances include: - Yimray Sunshine: +8.76% with a market cap of 3.3 billion - Aidi Kang Holdings: +6.81% with a market cap of 3.7 billion - MicroPort Scientific: +6.49% with a market cap of 27.7 billion - Alibaba Health: +2.77% with a market cap of 959 billion [1]. Group 2: ETF Launch and Characteristics - The newly launched Hong Kong Stock Connect Healthcare ETF (159137) aims to track the healthcare innovation index, covering key sectors such as CXO, AI healthcare, medical devices, and innovative drugs [3]. - The healthcare theme index has shown high elasticity and volatility, with a maximum increase of over 148% during the last healthcare bull market, significantly outperforming comparable indices [3][4]. Group 3: Recent Developments and Innovations - Recent advancements in brain-computer interfaces and AI healthcare have led to increased attention in the healthcare sector, with OpenAI launching ChatGPTHealth and Neuralink planning large-scale production of brain-computer interface devices by 2026 [4][5]. - Tsinghua University announced the development of an AI-driven high-throughput drug virtual screening platform, highlighting the growing intersection of AI and healthcare [5]. - The National Medical Products Administration in China is working on standards for medical devices using brain-computer interface technology, indicating a supportive regulatory environment [5]. Group 4: Investment Opportunities - The A-share market offers investment tools such as the largest healthcare ETF (512170), which includes 12 AI healthcare and brain-computer interface concept stocks, with a combined weight of over 36% [6]. - The current price-to-earnings ratio of the CSI Healthcare Index is 35.46, indicating a favorable valuation compared to historical averages [6].